Background: Higher dairy intake during adulthood has been associated with lower colorectal cancer risk. As colorectal carcinogenesis spans several decades, we hypothesised that higher dairy intake during adolescence is associated with lower risk of colorectal adenoma, a colorectal cancer precursor. Methods: In 27,196 females from the Nurses’ Health Study 2, aged 25–42 years at recruitment (1989), who had completed a validated high school diet questionnaire in 1998 and undergone at least one lower bowel endoscopy between 1998 and 2011, logistic regression for clustered data was used to calculate odds ratios (ORs) and 95% confidence intervals (CI). Results: Colorectal adenomas were diagnosed in 2239 women. Dairy consumption during adolescence was not associated with colorectal adenoma risk (OR highest vs. lowest [≥4 vs. ≤1.42 servings/day] quintile [95% CI] 0.94 [0.80, 1.11]). By anatomical site, higher adolescent dairy intake was associated with lower rectal (0.63 [0.42, 0.95]), but not proximal (1.01 [0.80, 1.28]) or distal (0.97 [0.76, 1.24]) colon adenoma risk. An inverse association was observed with histologically advanced (0.72 [0.51, 1.00]) but not non-advanced (1.07 [0.86, 1.33]) adenoma. Conclusions: In this large cohort of younger women, higher adolescent dairy intake was associated with lower rectal and advanced adenoma risk later in life.
|Number of pages||9|
|Journal||British journal of cancer|
|Publication status||Published - 2021 Mar 16|
Bibliographical noteFunding Information:
Competing interests Jeffrey Meyerhardt has received institutional research funding from Boston Biomedical, has served as an advisor/consultant to Ignyta and COTA Healthcare, and served on a grant review panel for the National Comprehensive Cancer Network funded by Taiho Pharmaceutical. Andrew T. Chan has previously served as a consultant to Bayer Pharma AG, Pfizer Inc., and Boehringer Ingelheim for topics unrelated to this manuscript. Charles S. Fuchs reports consulting role for Agios, Amylin Pharmaceuticals, Bain Capital, CytomX Therapeutics, Daiichi-Sankyo, Eli Lilly, Entrinsic Health, Evolveimmune Therapeutics, Genentech, Merck, Taiho, and Unum Therapeutics. He also serves as a Director for CytomX Therapeutics and owns unexercised stock options for CytomX and Entrinsic Health. He is a co-Founder of Evolveimmune Therapeutics and has equity in this private company. He had provided expert testimony for Amylin Pharmaceuticals and Eli Lilly. Shuji Ogino is a member of the Editorial Board of British Journal of Cancer. All other authors declare no competing interests Funding information The Nurses’ Health Study II was funded by the National Cancer Institute, National Institutes of Health (U01 CA176726, R01 CA67262, and U01 HL145386) and this project was funded by grants R03 CA197879 (to KW), R21 CA222940 to (K.W. and R. Nishihara), R21 CA230873 (to K.W. and S.O.), K99 CA215314 (to M.S.), R00 CA215314 (to M.S.), R35 CA197735 (to SO), R35 CA253185 (to A.T.C.), K07 CA218377 (to Y.C.) and K07 CA188126 (to X.Z.). This work was also in part supported by an Investigator Initiated Grant from the American Institute for Cancer Research (AICR) to K.W. In addition, this work was supported by American Cancer Society Research Scholar Grant (RSG130476 to X.Z.), the American Cancer Society Research Mentored Research Scholar Grant (MRSG-17-220-01 to M.S.), the Stuart and Suzanne Steele MGH Research Scholar Award (ATC), the Raymond P. Lavietes Foundation and the National Comprehensive Cancer Network Young Investigator Awards (to Y.C.), the Bill and Melinda Gates Foundation (to W.C.W.) and the Breast Cancer Research Fund (to W.C.W.). Open Access funding enabled and organized by Projekt DEAL.
© 2020, The Author(s).
All Science Journal Classification (ASJC) codes
- Cancer Research